Medivir Capital Markets Meeting on 26 March 2015

Stockholm, Sweden — Medivir AB (OMX: MVIR) today announces that a Capital Markets Meeting will be arranged for investors, analysts and journalists on Thursday 26 March at 2pm - 4.30pm CEST, in Stockholm.

CEO Niklas Prager and members of the Management team will present the company’s operations and give an update about our pharmaceuticals and R&D projects.

Other participants include Ola Burmark (CFO), Christine Lind (EVP Strategic Business Development), Richard Bethell (EVP Discovery Research), Charlotte Edenius (EVP Development) and Henrik Krook (EVP Commercial).

13.30-14.00             Coffee with the opportunity to meet the Medivir Management Team.

Meeting time:        Thursday 26 March, at 2pm - 4.30pm CEST
Venue:                   Conference Center Nio Rum, Hamngatan 2, Stockholm
Invitation for:         Institutional investors, analysts and media
Registration:         
To participate, please register at; hearings@financialhearings.com, no later than 23 March.

The event will also be available on-line via Webcast accessible through Medivir’s website; www.medivir.com.

Registration for investors, analysts and journalists
To participate, please register at; hearings@financialhearings.com, no later than 23 March.

For further information, please contact:
Niklas Prager, CEO Medivir AB, phone +46 (0)8-407 64 30.
Ola Burmark, CFO Medivir AB, mobile +46 (0)725 480580.

About Medivir
Medivir is a research based pharmaceutical company with a research focus on infectious diseases and oncology. We have a leading competence within protease inhibitor design and nucleotide/nucleoside science and we are dedicated to develop innovative pharmaceuticals that meet great unmet medical need. Our commercial organization provides a growing portfolio of specialty care pharmaceuticals on the Nordic market. Medivir is listed on the Nasdaq Stockholm Mid Cap List.

Tags:

About Us

Medivir is a pharmaceutical company with a focus on oncology. We have a leading competence within protease inhibitors and nucleotide/nucleoside science and we are dedicated to innovative pharmaceuticals that meet great unmet medical needs. Medivir's clinical pipeline consists of remetinostat for cutaneous T-cell lymphoma, currently in phase II, birinapant in combination with Keytruda for solid tumors, currently in phase I, MIV-818, a nucleotide prodrug drug for liver cancer that recently entered into a phase I clinical trial, and MIV-711, a potentially disease-modifying osteoarthritis candidate drug with fresh and promising data from the recent phase IIa extension study. Medivir is listed on the Nasdaq Stockholm Mid Cap List (ticker: MVIR). www.medivir.com.

Subscribe

Documents & Links